SMN2 and proximal spinal muscular atrophy: Nusinersen, the first DMT approved for SMA in the US, is an antisense oligonucleotide (ASO) administered intrathecally that modifies the splicing of SMN2 precursor mRNA to increase levels of full-length SMN protein (5–7).